Barbarajean Magnani, PhD, MD, FCAP, discusses IHC reporting. “Any accrediting organizations should view [IHC] not as a stain, but as an immunoassay, because we’re using it differently than we did 40 years ago,” Dr. Magnani told OncLive.
For the full article click here: Nuances of HER2 Expression Underscore Need for More Precise Testing in Breast Cancer